Posts

Posted on

MATSON ANNOUNCES PRELIMINARY 4Q25 RESULTS, PROVIDES 2026 OUTLOOK AND ANNOUNCES 4Q25 EARNINGS CALL DATE

PR Newswire

  • Expects 4Q25 consolidated operating income to be $135.0 to $145.0 million
  • Expects 4Q25 net income and diluted EPS to be $131.3 to $146.3 million and $4.22 to $4.70, respectively
  • 4Q25 diluted EPS includes a benefit of approximately $0.77 due to positive income tax adjustments
  • Expects full year 2026 consolidated operating income to approach the level achieved in full year 2025
  • Repurchased approximately 0.7 million shares in 4Q25

HONOLULU, Jan. 14, 2026 /PRNewswire/ — Matson, Inc. (“Matson” or the “Company”) (NYSE: MATX) today announces preliminary fourth quarter financial results, provides 2026 outlook for consolidated operating income and announces that its fourth quarter earnings call will be held on February 24, 2026.

Matt Cox, Matson’s Chairman and Chief Executive Officer, commented, “Matson had a solid finish to the year with consolidated fourth quarter results that exceeded our expectations. During the quarter, our China service saw higher than expected freight rates and volume driven by strong e-commerce and e-goods demand. Our China service benefited from strong freight demand in our key customer segments as well as a more stable trading environment in the Transpacific tradelane as a result of the U.S.-China trade and economic deal announced on October 30, 2025, which reduced uncertainty regarding tariffs, port entry fees, global trade and other geopolitical factors. Looking ahead, for full year 2026 we expect consolidated operating income to approach the level achieved in full year 2025 based on our expectations of continued solid U.S. consumer demand and a stable trading environment in the Transpacific tradelane.”

Mr. Cox added, “For the fourth quarter 2025, we expect consolidated operating income to be $135.0 to $145.0 million. We also expect fourth quarter 2025 net income and diluted EPS to be $131.3 to $146.3 million and $4.22 to $4.70, respectively. Fourth quarter 2025 diluted EPS includes a benefit of approximately $0.77 per share due to positive income tax adjustments. We will provide more details on our fourth quarter and full year 2025 financial performance and 2026 outlook on our earnings call on February 24, 2026.”

Fourth Quarter Tradelane Volume (Forty-foot equivalent units (FEU)) (1)(2)(3):

For the three months ended December 31, 2025 compared to the three months ended December 31, 2024 and on a FEU basis: 

  • Hawaii container volume increased 0.6 percent primarily due to higher general demand;
  • Alaska container volume decreased 3.3 percent primarily due to one less northbound sailing compared to the year ago period, partially offset by higher AAX volume;
  • China container volume was 7.2 percent lower;
  • Guam container volume was 4.4 percent higher primarily due to higher general demand; and
  • Other containers volume increased 11.6 percent.

________________________

(1)

Approximate volume included for the period are based on the voyage departure date, but revenue and operating income are adjusted to reflect the
percentage of revenue and operating income earned during the reporting period for voyages in transit at the end of each reporting period.

(2)

China volume includes containers from China and other Asia origins.

(3)

Other containers includes containers from services in various islands in Micronesia and the South Pacific, and Okinawa, Japan.

Other Items

  • SSAT Impairment Charge Last Year: In the fourth quarter 2024, operating income, net income and diluted EPS included an impairment charge related to the write-down of a terminal operating lease asset at SSAT, which impacted fourth quarter 2024 operating income, net income and diluted EPS by $18.4 million, $14.0 million and $0.42 per share, respectively.

  • Income Taxes: Income taxes for the fourth quarter 2025 is estimated to be $6.0 to $11.0 million, which implies an effective tax rate for the quarter of 3.9 to 7.7 percent, due to the benefit of positive income tax adjustments. Compared to an effective income tax rate of 22.0 percent, the midpoint of this fourth quarter income taxes range would benefit diluted EPS by approximately $0.77 per share for the quarter.

  • Liquidity and Debt: Matson’s cash and cash equivalents as of December 31, 2025 was approximately $141.9 million, which excluded $532.7 million in cash on deposit within the Capital Construction Fund (“CCF”). Total debt as of December 31, 2025 was $361.2 million.(4) 

  • Share Repurchases: During the fourth quarter of 2025, Matson repurchased approximately 0.7 million shares for a total cost of $78.1 million.(5) As of December 31, 2025, the Company had approximately 1.1 million shares remaining in its share repurchase program.

A slide presentation that accompanies this press release is available on the Company’s website at www.matson.com, under Investors.

(4)     Total debt is presented before any reduction for deferred loan fees as required by GAAP.
(5)     Includes stock repurchased during the quarter but not settled and taxes on share repurchases that will be paid after the quarter end

Teleconference and Webcast

A conference call is scheduled on February 24, 2026 at 4:30 p.m. ET when Matt Cox, Chairman and Chief Executive Officer, and Joel Wine, Executive Vice President and Chief Financial Officer, will discuss Matson’s fourth quarter results.

Date of Conference Call:

Tuesday, February 24, 2026

Scheduled Time:

4:30 p.m. ET / 1:30 p.m. PT / 11:30 a.m. HT

The conference call will be broadcast live along with an additional slide presentation on the Company’s website at www.matson.com, under Investors. 

Participants may register for the conference call at:


https://register-conf.media-server.com/register/BI2f86b7aed35545c9bacf93a43078cde7

Registered participants will receive the conference call dial-in number and a unique PIN code to access the live event. While not required, it is recommended you join 10 minutes prior to the event starting time. A replay of the conference call will be available approximately two hours after the event by accessing the webcast link at www.matson.com, under Investors.

About the Company

Founded in 1882, Matson (NYSE: MATX) is a leading provider of ocean transportation and logistics services. Matson provides a vital lifeline of ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, and Guam, and to other island economies in Micronesia. Matson also operates premium, expedited services from China to Long Beach, California, which includes transshipment of cargo from other Asia origins, provides service to Okinawa, Japan and various islands in the South Pacific, and operates an international export service from Alaska to Asia. The Company’s fleet of owned and chartered vessels includes containerships, combination container and roll-on/roll-off ships and barges. Matson Logistics, established in 1987, extends the geographic reach of Matson’s transportation network throughout North America and Asia. Its integrated, logistics services include rail intermodal, highway brokerage, warehousing, freight consolidation, supply chain management, and freight forwarding to Alaska. Additional information about the Company is available at www.matson.com.

Forward-Looking Statements

Statements in this news release that are not historical facts are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation those statements regarding outlook; operating income; consumer demand; and the trading environment. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement, including but not limited to risks and uncertainties relating to repeal, invalidation, substantial amendment or waiver of the Jones Act or changes in its application, or the Company were determined not to be a United States citizen under the Jones Act; changes in macroeconomic conditions, geopolitical developments, or governmental policies; our ability to offer a differentiated service in China for which customers are willing to pay a significant premium; new or increased competition; our relationship with customers and vendors and changes in related agreements; fuel prices, our ability to collect fuel-related surcharges and/or the cost or limited availability of required fuels; evolving regulations and stakeholder expectations related to sustainability matters; timely or successful completion of fleet upgrade initiatives; the Company’s vessel construction agreements with Philly Shipyard; the occurrence of weather, natural disasters, maritime accidents, spill events and other physical and operating risks; transitional and other risks arising from climate change; actual or threatened health epidemics, outbreaks of disease, pandemics or other major health crises; significant operating agreements and leases that may not be renewed/replaced on favorable or acceptable terms; any unexpected dry-docking or repair costs; joint venture relationships; conducting business in foreign shipping markets, including the imposition of tariffs or a change in international trade policies; any delays or cost overruns related to the modernization of terminals; war, actual or threatened terrorist attacks, efforts to combat terrorism and other acts of violence; consummating and integrating acquisitions; work stoppages or other labor disruptions caused by our unionized workers and other workers or their unions in related industries; loss of key personnel or failure to adequately manage human capital; the use of our information technology and communication systems and cybersecurity attacks; changes in our credit profile, disruptions of the credit markets, changes in interest rates and our future financial performance; our ability to access the debt capital markets; continuation of the Title XI and CCF programs; costs to comply with and liability related to numerous safety, environmental, and other laws and regulations; and disputes, legal and other proceedings and government inquiries or investigations. These forward-looking statements are not guarantees of future performance. This release should be read in conjunction with our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and our other filings with the SEC through the date of this release, which identify important factors that could affect the forward-looking statements in this release. We do not undertake any obligation to update our forward-looking statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/matson-announces-preliminary-4q25-results-provides-2026-outlook-and-announces-4q25-earnings-call-date-302661834.html

SOURCE Matson, Inc.

Posted on

Corcept Therapeutics Incorporated Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights – CORT

Corcept Therapeutics Incorporated Investigated on Behalf of Investors – Contact the DJS Law Group to Discuss Your Rights – CORT

LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. On December 31, 2026, Corcept revealed that the FDA had issued “a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.” The Company added, “the FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the company’s GRADIENT trial provided confirmatory evidence, the Agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” Corcept shares fell by more than half on this news.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Posted on

ARDT Investors Have Opportunity to Lead Ardent Health, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, Jan. 14, 2026 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Ardent Health, Inc. (NYSE: ARDT) between July 18, 2024 and November 12, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 9, 2026.

So What: If you purchased Ardent Health securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Ardent Health class action, go to https://rosenlegal.com/submit-form/?case_id=50392 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made misrepresentations regarding Ardent Health’s accounts receivable. Defendants publicly reported Ardent Health’s accounts receivable on a quarterly basis. They further stated that Ardent Health employed an active monitoring process to determine the collectability of its accounts receivable, and that this process included “detailed reviews of historical collections” as a “primary source of information.” Further, defendants represented that Ardent Health considered “trends in federal and state governmental healthcare coverage” and that its “management determines [when an] account is uncollectible, at which time the account is written off.” When defendants began to reveal increased claim denials by third-party payors, they downplayed the issue, stating that the increased payor denials were “turning [] more into a slow pay versus not getting paid,” and did not write-off the uncollectible accounts. In addition, defendants represented that Ardent Health maintained professional malpractice liability insurance in amounts “sufficient to cover claims arising out of [its] operations[.]” In truth, Ardent Health did not primarily rely on “detailed reviews of historical collections” in determining collectability of accounts receivable nor did “management determine[] [when an] account is uncollectible.” Instead, Ardent Health’s accounts receivable framework “utilized a 180-day cliff at which time an account became fully reserved.” This allowed Ardent Health to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts. And Ardent Health did not even maintain professional malpractice liability insurance in amounts “sufficient to cover claims arising out of [its] operations[.]” In truth, Ardent Health’s professional liability reserves were insufficient to cover “significant social inflationary pressure in medical malpractice cases the past several years,” which had been an “increasing dynamic year-over-year” in Ardent Health’s New Mexico market. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ardent Health class action, go to https://rosenlegal.com/submit-form/?case_id=50392 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ardt-investors-have-opportunity-to-lead-ardent-health-inc-securities-fraud-lawsuit-302661714.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

ARE Investors Have Opportunity to Lead Alexandria Real Estate Equities, Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK, Jan. 14, 2026 /PRNewswire/ — 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alexandria Real Estate Equities, Inc. (NYSE: ARE) between January 27, 2025 and October 27, 2025, both dates inclusive (the “Class Period”), of the important January 26, 2026 lead plaintiff deadline.

So what: If you purchased Alexandria Real Estate Equities securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Alexandria Real Estate Equities class action, go to https://rosenlegal.com/submit-form/?case_id=48531 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants provided investors with material information concerning Alexandria Real Estate’s expected revenue and funds from operations (“FFO”) growth for the 2025 fiscal year, particularly as it related to the growth of Alexandria Real Estate’s real estate operations. The defendants’ statements included, among other things, confidence in Alexandria Real Estate Equities’ lease activity, occupancy stability, and ability to develop its tenant pipeline.

According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of its Long Island City (“LIC”) property. In particular, Alexandria Real Estate’s claims and confidence about the leasing value of the LIC property as a life-science destination. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Alexandria Real Estate Equities class action, go to https://rosenlegal.com/submit-form/?case_id=48531 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/are-investors-have-opportunity-to-lead-alexandria-real-estate-equities-inc-securities-fraud-lawsuit-302661710.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

Bristow Group Announces Pricing of $500 Million Senior Secured Notes in an Upsized Private Offering

PR Newswire

HOUSTON, Jan. 14, 2026 /PRNewswire/ — Bristow Group Inc. (NYSE: VTOL) (the “Company” or “Bristow”) announced today the pricing of an upsized private offering of $500 million aggregate principal amount of 6.75% senior secured notes due 2033 (the “notes”) to eligible purchasers pursuant to Rule 144A and Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the offering is expected to occur on January 26, 2026 and is subject to the satisfaction of customary closing conditions.

The notes will mature on February 1, 2033 and will be issued at par. The notes will pay interest semi-annually and will be fully and unconditionally guaranteed, jointly and severally, on a senior secured basis, by the Company’s existing material, wholly owned domestic subsidiaries and certain existing material, foreign subsidiaries, as well as certain future subsidiaries. The notes will be secured by first-priority liens, subject to limited exceptions, on collateral that will consist of certain helicopters and related assets, together with substantially all of the other tangible and intangible property assets of the Company and the subsidiary guarantors (other than certain excluded assets), including approximately 119 pledged aircraft.

The Company will irrevocably deposit a portion of the net proceeds from the offering with the trustee under the indenture (the “2028 Notes Indenture”) governing its 6.875% Senior Secured Notes due 2028 (the “2028 Notes”) in an amount sufficient to redeem the 2028 Notes in full on March 1, 2026 and fund the payment of the principal, premium and interest to, but not including, such redemption date and all other sums payable under the 2028 Notes Indenture with respect to the 2028 Notes. As a result (and at the time) of such deposit, the 2028 Notes Indenture will be satisfied and discharged in accordance with its terms with respect to the 2028 Notes (the “Satisfaction and Discharge”). The Company intends to use any remaining net proceeds from the offering for general corporate purposes.

The notes are being offered and sold to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act, and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The offer and sale of the notes and the related subsidiary guarantees have not been and will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the notes or any other securities, nor shall there be any sale of the notes or any other securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. Any offers of the notes shall be made in the United States only by means of a private offering circular pursuant to Rule 144A under the Securities Act, and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act.

This press release does not constitute a notice of redemption with respect to the 2028 Notes.

About Bristow Group

Bristow Group Inc. is the leading global provider of innovative and sustainable vertical flight solutions. Bristow primarily provides aviation services to a broad base of offshore energy companies and government entities. Our aviation services include personnel transportation, search and rescue (“SAR”), medevac, fixed-wing transportation, unmanned systems and ad hoc helicopter services. Our business is comprised of three operating segments: Offshore Energy Services, Government Services and Other Services. Our energy customers charter our helicopters primarily to transport personnel to, from and between onshore bases and offshore production platforms, drilling rigs and other installations. Our government customers primarily outsource SAR activities whereby we operate specialized helicopters and provide highly trained personnel. Our other services include fixed-wing transportation services through a regional airline in Australia and dry-leasing aircraft to third-party operators in support of other industries and geographic markets.

Bristow currently has customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, Ireland, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the United Kingdom and the United States.

Forward-Looking Statements Disclosure

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements about our future business, strategy, operations, capabilities and results; financial projections; plans and objectives of our management; expected actions by us and by third parties, including our customers, competitors, vendors and regulators; and other matters. Some of the forward-looking statements can be identified by the use of words such as “believes,” “belief,” “forecasts,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “would,” “could,” “should” or other similar words; however, all statements in this press release, other than statements of historical fact or historical financial results, are forward-looking statements. Without limiting the generality of the foregoing, such forward-looking statements include statements regarding the use of proceeds from the offering and the Satisfaction and Discharge of the 2028 Notes. Our forward-looking statements reflect our views and assumptions on the date hereof regarding future events and operating performance. We believe that they are reasonable, but they involve significant known and unknown risks, uncertainties, assumptions and other factors, many of which may be beyond our control, that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks, uncertainties and factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, and in particular, the risks discussed in Part I, Item 1A, “Risk Factors” of such report and those discussed in other documents we file with the Securities and Exchange Commission. Accordingly, you should not put undue reliance on any forward-looking statements. There can be no assurance that the offering of the notes will be consummated on the terms described herein or at all.

All forward-looking statements in this press release are qualified by these cautionary statements and are only made as of the date thereof. The forward-looking statements in this press release should be evaluated together with the many uncertainties that affect our businesses, particularly those discussed in greater detail in Part I, Item 1A, “Risk Factors” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A, “Risk Factors” of our subsequent Quarterly Reports on Form 10-Q. We disclaim any obligation or undertaking, other than as required by law, to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any change in events, conditions or circumstances on which the forward-looking statement is based, whether as a result of new information, future events or otherwise.

Investors

Bristow Group Inc.
Jennifer Whalen
[email protected]

Media

Bristow Group Inc.
Adam Morgan
[email protected] 

Cision View original content:https://www.prnewswire.com/news-releases/bristow-group-announces-pricing-of-500-million-senior-secured-notes-in-an-upsized-private-offering-302661772.html

SOURCE Bristow Group

Posted on

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference

  • Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presence
  • Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipeline
  • Multiple global registrational Phase III trials are progressing rapidly

ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its Chairman and CEO, Dajun Yang, M.D., Ph.D., presented at the 44th Annual J.P. Morgan Healthcare Conference. In the corporate presentation, Dr. Yang provided an overview of milestone achievements in 2025 and outlined the Company’s global innovation strategy for 2026.

Dr. Yang said, “The annual J.P. Morgan Healthcare Conference provides an important platform for us to engage with peers from around the world and showcase our strategy and progress. For Ascentage Pharma, 2025 was a critical year in which we accelerated our global expansion, advancing product commercialization, global clinical development, and pipeline innovation. To date, we have built a powerful engine for innovation in hematologic malignancies and solid tumors, harnessing a diverse range of mechanisms and synergies between core components that include our commercialized products, late-stage programs in solid tumors, as well as our early-stage innovative therapies that utilize our cutting-edge protein degradation technology. This multi-faceted global portfolio of products and clinical programs has positioned Ascentage Pharma well for future challenges and laid a solid foundation for sustained growth. Entering 2026, Ascentage Pharma is opening a new chapter on its global innovation strategy. We remain steadfastly committed to our mission of addressing unmet clinical needs around the world and accelerating the development of our promising innovative therapeutics for the benefit of patients worldwide.”

Dual-Engine Driven by Two Core Products: Building a Global Hematologic Malignancy Treatment Landscape

The Company’s two core products, the third-generation BCR-ABL inhibitor Olverembatinib and the Bcl-2 inhibitor Lisaftoclax, both achieved significant progress in 2025 and represent main growth drivers for 2026. Together, they generate powerful “dual-engine” effects that will drive the Company’s future growth and support the development of a global portfolio of innovative therapies covering a broad range of hematologic malignancies.

Dr. Yang continued, “In the past year, Ascentage Pharma has made progress across multiple clinical studies underway for its key drug candidates globally, and presented data from these studies at prestigious international academic congresses. These data underscored the Company’s potential in delivering clinical breakthroughs for challenging hematologic malignancies and the global competitiveness of its products.”

Developing the Next-Generation BTK Degrader: Propelling Strategic Expansion of Global Innovative Pipeline

Achieving breakthroughs in translational medicine and the development of a diverse pipeline, Ascentage Pharma has received an investigational new drug (IND) clearance from the U.S. FDA for APG-3288, the first novel, highly potent and selective BTK degrader developed utilizing Ascentage Pharma’s proprietary proteolysis-targeting chimera (PROTAC) technology platform. This clearance initiates Ascentage Pharma’s clinical development in the field of targeted degradation and lays a strong foundation for future exploration of the combinatory potential between APG-3288 and the Company’s existing proprietary small-molecule agents.

Adding to the dual-engine effect generated by Olverembatinib and Lisaftoclax, other assets in the Company’s pipeline are also making rapid progress, forming a portfolio of advancing programs. The Company’s other key clinical programs include:

  • APG-5918 (EED inhibitor): Preclinical data have shown therapeutic potential in hematologic malignancies (multiple myeloma and T-cell lymphoma) and solid tumors (prostate cancer). For non-hematologic indications, the Company is conducting a Phase I study in patients with anemia in China.
  • APG-2449 (FAK/ALK/ROS1 inhibitor): Has entered global registrational Phase III studies in non-small cell lung cancer (NSCLC), representing a major breakthrough in the Company’s expansion into solid tumors.
  • Alrizomadlin (APG-115; MDM2-p53 inhibitor): Currently being evaluated in a Phase II study and has shown clinical potential in solid tumors such as adenoid cystic carcinoma (ACC).
  • Pelcitoclax (APG-1252; Bcl-2/Bcl-xL inhibitor): Currently being evaluated in a Phase II study, having shown clinical potential in a range of tumor types including EGFR-mutant NSCLC, relapsed/refractory non-Hodgkin lymphoma, ovarian cancer, and endometrial carcinoma.

Outlook for 2026

In the presentation, Dr. Yang touched on a number of potential milestones and catalysts expected in 2026 as follows:

  • In global clinical development: Advance multiple registrational Phase III studies including GLORA, GLORA-4, POLARIS-1, and POLARIS-2.
  • In commercialization: Continued growth in commercial sales, broader patient accessibility and coverage across 1,500 hospitals; inclusion in NRDL coverage of Lisaftoclax in China.
  • In early-stage clinical programs: BTK Protein Degrader APG-3288 global Phase I PK, safety, tolerability, efficacy data, including U.S. and China; advancement of EED Inhibitor APG-5918 in oncology and anemia in the U.S. and China.

*Olverembatinib, Lisaftoclax, Alrizomadlin, Pelcitoclax, APG-3288, APG-5918, and APG-2449 are currently under investigation and have not yet been approved by the U.S. FDA.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.

The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.

The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations:

Stella Yang
Ascentage Pharma
[email protected]
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:

Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012



Posted on

KKR Completes US$2.5 Billion Asia Private Credit Fundraise

KKR Completes US$2.5 Billion Asia Private Credit Fundraise

HONG KONG–(BUSINESS WIRE)–
KKR, a leading global investment firm, today announced the completion of a US$2.5 billion fundraise focused on committing capital to privately originated performing credit investments in Asia Pacific. The fundraise includes US$1.8 billion in KKR Asia Credit Opportunities Fund II (“ACOF II” or the “Fund”) and US$700 million raised from separately managed accounts focused on the same types of investment opportunities.

At close, the Fund is the largest pan-regional performing private credit fund in Asia Pacific. This closely follows KKR’s inaugural Asia Pacific-dedicated private credit fund, KKR Asia Credit Opportunities Fund, which closed at US$1.1 billion in 2022 as the largest inaugural pan-regional fund focused on performing credit. KKR’s Asia Credit platform has signed 10 investments through ACOF II representing US$1.9 billion in KKR commitments, including other pools of capital, and a total transaction volume of US$4.6 billion.

Diane Raposio, Partner and Head of Asia Credit & Markets at KKR, said “Asia is a key pillar of KKR’s global credit strategy. The close of ACOF II demonstrates the breadth and scale we have built across our Asia credit platform, spanning both private and liquid markets. We are seeing growing investor demand for allocation to credit in the region. Our pan-Asia approach and ability to leverage the broader KKR Asia platform uniquely positions us to continue sourcing and executing interesting opportunities across the region for our investors.”

KKR’s Asia Credit platform seeks to provide bespoke private credit solutions to companies and sponsors which harness the strength of KKR’s investment capabilities and its expertise as one of the largest credit managers globally. The Asia Credit team leverages KKR’s local and global resources to source, diligence, and execute investment opportunities to provide borrowers with customized financing and value creation potential while ensuring lender capital protections. Like its predecessor, ACOF II will pursue investments in performing privately originated credit and target opportunities across three primary investing themes, including senior and unitranche direct lending, capital solutions, and collateral-backed investments.

SJ Lim, Managing Director and Head of Asia Private Credit at KKR, said “Private credit remains a relatively nascent yet compelling opportunity across the region. We see strong demand for private credit as an important tool for sponsors or corporates seeking flexible financing solutions and bespoke, partnership-oriented capital to support growth and meet their diverse needs. Our performing credit strategy is based on the same long term structural themes such as rising consumption, urbanization and digitalization that have underpinned the growth of private markets in Asia.”

The Fund received strong support from a diverse group of new and existing investors, including insurance companies, public and corporate pension funds, sovereign wealth funds, family offices, banks, corporates, and asset managers.

In Asia Pacific, KKR has closed over 60 investments through its Asia Credit strategy since 2019, accounting for approximately US$8.3 billion invested by KKR and total transaction value of US$27.5 billion. This has included providing acquisition financing and bespoke capital solutions for companies and financial sponsors in the healthcare, education, real estate, logistics, and infrastructure sectors. KKR targets credit investments in Australia, Greater China, India, Japan, Korea, New Zealand, and Southeast Asia.

Over the past two decades KKR has built one of the largest credit investment platforms globally with the ability to invest across the capital structure and liquidity spectrum. These capabilities are paired with KKR’s approach to proprietary sourcing, capital preservation, and active portfolio management to seek out long-term capital appreciation and attractive risk-adjusted returns. Today, KKR manages approximately US$282 billion of credit assets globally, including approximately US$143 billion in leveraged credit, approximately US$131 billion in private credit, and approximately US$8 billion in strategic investments, as of September 30, 2025. KKR has a team of approximately 250 credit investment professionals across 12 offices globally.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Media Contact

Wei Jun Ong

[email protected]

KEYWORDS: Asia Pacific Hong Kong

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

STUB Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against StubHub Holdings, Inc. (STUB)

PR Newswire

RADNOR, Pa., Jan. 14, 2026 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against StubHub Holdings, Inc. (“StubHub”) (NYSE: STUB) on behalf of those who purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with StubHub’s September 2025 initial public offering. The lead plaintiff deadline is January 23, 2026.


CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:


If you suffered StubHub losses, contact KTMC at
:
https://www.ktmc.com/new-cases/stubhub-holdings-inc?utm_source=PR_Newswire&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. 


DEFENDANTS’ ALLEGED MISCONDUCT:

The complaint alleges that, in the Offering Documents, Defendants made false and/or misleading statements and/or failed to disclose that: (1) StubHub was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on StubHub’s free cash flow, including trailing 12 months free cash flow; (3) as a result, StubHub’s free cash flow reports were materially misleading; and (4) that, as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

YouTube Video: https://youtube.com/shorts/OdXl5OZsZXE?feature=share


THE LEAD PLAINTIFF PROCESS:

StubHub investors may, no later than January 23, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.


Kessler Topaz Meltzer & Check, LLP
 encourages StubHub investors who have suffered significant losses to contact the firm directly to acquire more information.

SIGN UP FOR THE STUBHUB CASE AT
:
https://www.ktmc.com/new-cases/stubhub-holdings-inc?utm_source=PR_Newswire&mktm=PR


ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:


Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected] 

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stub-investor-alert-a-securities-fraud-class-action-lawsuit-has-been-filed-against-stubhub-holdings-inc-stub-302660849.html

SOURCE Kessler Topaz Meltzer & Check, LLP

Posted on

Allegiant Announces Senior Leadership Promotions

PR Newswire

LAS VEGAS, Jan. 14, 2026 /PRNewswire/ — Allegiant Travel Company (NASDAQ: ALGT) today announced several senior leadership promotions that strengthen organizational depth and position the company for long‑term success as it enters a pivotal next phase, including the establishment of an Integration Management Office.

The promotions include Michael Broderick as Senior Vice President & Chief Integration Officer, Rebecca Aretos as Senior Vice President, Finance & Chief Accounting Officer, and Asad Shaikh as Senior Vice President, Corporate Finance & Treasurer.

“These leaders have decades of industry experience and have consistently delivered exceptional results while shaping the culture, performance and reputation that define Allegiant today,” said Robert Neal, President & Chief Financial Officer. “Their leadership, expertise and commitment to our people and customers will be critical as we navigate upcoming milestones and build the foundation for Allegiant’s future growth. These promotions reflect past achievements and our confidence in their ability to guide Allegiant into its next chapter.”

Leadership appointments include:

Michael Broderick — Senior Vice President & Chief Integration Officer

Michael Broderick has been appointed Chief Integration Officer and will lead Allegiant’s Integration Management Office (IMO), overseeing integration planning related to the company’s proposed combination with Sun Country. He will coordinate cross‑functional planning, decision‑making and communication to ensure a thoughtful, well‑organized approach that prioritizes team members and customers.

Since joining Allegiant in 2017, Broderick has built a strong enterprise and operational track record, most recently overseeing Procurement, Financial Planning & Analysis (FP&A) and Airport Affairs. Prior to joining Allegiant, he held leadership roles at US Airways, Sabre, and American Airlines.

Rebecca Aretos — Senior Vice President, Finance & Chief Accounting Officer

Rebecca Aretos has been promoted to Senior Vice President, Finance & Chief Accounting Officer. Aretos joined Allegiant in 2007 and has been a long‑standing leader within the Finance organization, known for her technical expertise, governance focus, and commitment to transparency. She played a central role in leading the company’s major transition to its SAP enterprise resource planning system.

In her expanded role, she will continue overseeing Accounting while assuming leadership of the FP&A organization, reflecting the importance of integrated planning, forecasting strength and enhanced decision support as the business scales.

Asad Shaikh — Senior Vice President, Corporate Finance & Treasurer

Asad Shaikh has been promoted to Senior Vice President, Corporate Finance & Treasurer. Since joining Allegiant in 2013, Asad has strengthened the company’s long‑term financial strategy through disciplined leadership of key fleet decisions. He has guided Airbus fleet transactions and played a pivotal role in negotiating and executing Allegiant’s Boeing 737 MAX order.

Since 2024, he has overseen Corporate Finance and Treasury with a focus on liquidity, aircraft financing and balance‑sheet management. His expanded role includes oversight of the Procurement organization to further align strategic sourcing decisions with Allegiant’s long‑term financial outcomes.

About the Integration Management Office (IMO)

The newly established IMO will report to Allegiant’s CEO, Gregory C. Anderson, and coordinate integration planning and execution related to Allegiant’s proposed acquisition of Sun Country. Allegiant and Sun Country will continue to operate as separate companies until the transaction closes and all required approvals are obtained.

Allegiant – Together We Fly™

Las Vegas-based Allegiant (NASDAQ: ALGT) is an integrated travel company with an airline at its heart, focused on connecting customers with the people, places and experiences that matter most. Since 1999, Allegiant Air has linked travelers in small-to-medium cities to world-class vacation destinations with all-nonstop flights and industry-low average fares. Today, Allegiant serves communities across the nation, with base airfares less than half the cost of the average domestic roundtrip ticket. For more information, visit us at Allegiant.com. Media information, including photos, is available at http://gofly.us/iiFa303wrtF

Media Contact

Phone: 702-800-2020
Email: [email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/allegiant-announces-senior-leadership-promotions-302661733.html

SOURCE Allegiant Travel Company

Posted on

Shareholders that lost money on Varonis Systems, Inc. (VRNS) should contact The Gross Law Firm about pending Class Action – VRNS

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Varonis Systems, Inc. (NASDAQ: VRNS).

Shareholders who purchased shares of VRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/varonis-systems-inc-loss-submission-form/?id=183085&from=3

CLASS PERIOD: February 4, 2025 to October 28, 2025

ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Varonis’ ability to convert its existing customer base; notably, that it was not truly equipped to convince existing users of the benefits of converting to the SaaS offering or otherwise maintain those customers on its platform, resulting in significantly reduced ARR growth potential in the near-term. On October 28, 2025, Varonis announced its financial results for the third quarter of fiscal 2025, disclosing a significant miss to ARR and reducing its projections for the full fiscal year 2025, despite previously uplifting guidance for the previous two consecutive quarters. The Company attributed its results and lowered guidance on weaker than expected renewals and conversions in their federal and non-federal on-premises subscription business. Varonis further resultantly announced the end of life of the self-hosted solution and a 5% headcount reduction. Following this news, Varonis’ common stock declined dramatically. From a closing market price of $63.00 per share on October 28, 2025, Varonis’ stock price fell to $32.34 per share on October 29, 2025, a decline of about 48.67% in the span of just a single day.

DEADLINE: March 9, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/varonis-systems-inc-loss-submission-form/?id=183085&from=3

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of VRNS during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 9, 2026. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903